PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has entered into a research collaboration with the laboratory of Ellen Puré, Ph.D., professor/associate vice president for Academic Affairs at The Wistar Institute. Dr. Puré’s research defines the role of fibroblast activation protein (FAP) in cancer, and she has demonstrated that genetically deleting or therapeutically targeting FAP significantly reduces tumor growth in mice. Advaxis will use these mouse models to explore the potential of FAP as a target for immune attack and as the basis for the development of a live attenuated Listeria vaccine using the company’s proprietary Lm-LLO technology.
